Forte Biosciences Inc (FBRX) — Cash Flow-to-Debt Ratio
Forte Biosciences Inc (FBRX) has a Cash Flow-to-Debt Ratio of -1.08x as of September 2025, meaning its operating cash flow of $-14.00 Million could theoretically repay -1% of its total liabilities ($12.99 Million) in one year. See FBRX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Forte Biosciences Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Forte Biosciences Inc across 10 annual periods. Also explore FBRX net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Forte Biosciences Inc (2015–2024)
Year-by-year debt coverage analysis for Forte Biosciences Inc. For market capitalisation and broader financial context, see FBRX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.39x | $-30.75 Million | $9.08 Million | ▲ +56.8% |
| 2023 | -7.83x | $-28.71 Million | $3.67 Million | ▼ -204.1% |
| 2022 | -2.57x | $-8.19 Million | $3.18 Million | ▲ +72.9% |
| 2021 | -9.49x | $-16.68 Million | $1.76 Million | ▼ -16.3% |
| 2020 | -8.16x | $-18.42 Million | $2.26 Million | ▼ -462.7% |
| 2019 | -1.45x | $-2.77 Million | $1.91 Million | ▼ -88.9% |
| 2018 | -0.77x | $-34.47 Million | $44.94 Million | ▲ +48.3% |
| 2017 | -1.48x | $-31.13 Million | $20.99 Million | ▼ -42.4% |
| 2016 | -1.04x | $-29.54 Million | $28.36 Million | ▼ -14.3% |
| 2015 | -0.91x | $-21.04 Million | $23.09 Million | — |